drugset / Trial / NCT02022852

Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer

NCT02022852 ↗

Phase 2 Unknown 80 enrolled Harbin Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Compared curative effect,safety and compliance between concurrent chemoradiotherapy and chemo-chemoradio-chemo sequential therapy in locally advanced mid/low rectal cancer.

Timeline

Start
2013-07
Primary completion
2015-07
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 850 mg/m2 —
Comparator Capecitabine Small molecule 1000 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications